A genetic variant in long non-coding RNA MALAT1 associated with survival outcome among patients with advanced lung adenocarcinoma: a survival cohort analysis

BMC Cancer

Research Article

Huan Guo¹  Yan-Sen Bai¹  Zhuo-Wang Chen¹  Ying Peng²  Wen-Hao Guo²  Jing-Jun Xiang²  Xiang-Qian Yin²  Qing Wang²  Jian-Zhong Wang²  Li-Ge Wu²  Ping Xu³ 

[1] Department of Occupational and Environmental Health and Ministry of Education Key Lab for Environment and Health, School of Public Health, Tongji Medical College, Huazhong University of Science and Technology, 13 Hangkong Rd, 430030, Wuhan, China;Department of Oncology, Wuhan Iron and Steel (Group) Corporation Staff-Worker Hospital, 32 Qinghua Road, 430085, Wuhan, China;Department of Oncology, Wuhan Iron and Steel (Group) Corporation Staff-Worker Hospital, 32 Qinghua Road, 430085, Wuhan, China;Department of Occupational and Environmental Health and Ministry of Education Key Lab for Environment and Health, School of Public Health, Tongji Medical College, Huazhong University of Science and Technology, 13 Hangkong Rd, 430030, Wuhan, China;

关键词: Lung cancer;    Survival;    Long non-coding RNA;    Metastasis-associated lung adenocarcinoma transcript 1 (MALAT1);   

DOI  :  10.1186/s12885-017-3151-6

 received in 2015-10-14, accepted in 2017-02-22,  发布年份 2017

来源: Springer

【 摘 要 】

BackgroundRecently studies have demonstrated that the long non-coding RNA (lncRNA) metastasis associated lung adenocarcinoma transcript 1 (MALAT1) may participate in the development and progression of lung cancer. In this study, we hypothesized that genetic variant of this lncRNA may affect the prognosis of lung cancer patients.MethodsWe conducted a follow-up study for 538 patients with non–small cell lung carcinoma (NSCLC), including 140 early-staged (stage I and II) and 398 advanced staged (stage III and IV) patients. The genetic variant rs3200401 in MALAT1 was then genotyped among this population by using TaqMan assay. The association of this variant with overall survival of these patients was further analyzed.ResultsIt was shown that among the advanced lung adenoma patients, subjects carrying rs3200401 CT and CT + TT genotypes had significantly longer median survival time (MST = 29.9, 28.9 vs. 19.3 month, Long-rank P = 0.019 and 0.024, respectively) and decreased death risks [crude HR (95% CI) = 0.65 (0.43–0.98) and 0.64 (0.44–0.95), P = 0.040 and 0.025, respectively], when compared to subjects wtih the MALAT1 rs3200401 CC genotype. However, the beneficial effect of rs3200401 was not seen among early NSCLC and advanced lung squamous cell carcinoma patients. We further tested the TCGA data, and found that a higher expression of MALAT1 was associated with metastatic of advanced lung adenocarcinoma but not with lung squamous cell carcinoma.ConclusionsThe rs3200401 T allele located on the lncRNA MALAT1 was associated with a better survival for advanced lung adenocarcinoma patients, which may offer a novel prognostic biomarker for this patient subgroup. However, these results need to be validated in larger populations of lung cancer and the biological function of this variant still warrants further investigation.

【 授权许可】

CC BY   
© The Author(s). 2017